Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
83 Phase 1 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Leukemia, lymphoma, and myeloma83 studies
Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
B-Non Hodgkin LymphomaPhase 1/2NCT05442515Papers
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
MyelofibrosisPhase 1NCT07379125
Therapeutic RSK1 Targeting in Myelofibrosis
Hairy Cell LeukemiaPhase 1NCT04815356Papers
Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromePhase 1NCT05986240
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Multiple MyelomaPhase 1NCT07200089
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Recurrent B Acute Lymphoblastic LeukemiaPhase 1NCT07532525
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Relapsed Multiple Myeloma After CAR T-Cell TherapyPhase 1NCT07200102
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Non-hodgkin LymphomaPhase 1NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Acute Myeloid Leukemia and Myelodysplastic Syndromes After Allogeneic TransplantPhase 1/2NCT06129734
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Refractory Acute Myeloid LeukemiaPhase 1NCT06017258Papers
CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
NPM1-Mutated AML in Remission After Allogeneic TransplantPhase 1NCT06440135
Ziftomenib Maintenance Post Allo-HCT
Relapsed/Refractory MyelomaPhase 1/2NCT06066359
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
Hodgkin's LymphomaPhase 1NCT02917083Papers
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Large B-cell LymphomaPhase 1NCT07052305
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Relapsed or Refractory Post-Transplant Lymphoproliferative DisorderPhase 1NCT06672705
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Relapsed/Refractory Acute Myeloid LeukemiaPhase 1NCT03874052Papers
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Relapsed or Refractory Acute Myeloid LeukemiaPhase 1NCT07661095
CRD3874-SI in People With Leukemia
Mantle Cell LymphomaPhase 1/2NCT06029309
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Acute Myeloid LeukemiaPhase 1/2NCT03214562Papers
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Relapsed or Refractory AML, MDS or CMMLPhase 1NCT04375631
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Non Hodgkin LymphomaPhase 1NCT07225439Papers
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Relapsed or Refractory Lymphomas and B-ALLPhase 1NCT07444632
CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
Relapsed or Refractory Acute Myeloid LeukemiaPhase 1NCT07025564Papers
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia